Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thyroid cancer (TC) is frequently associated with BRAF or RAS oncogenic mutations and RET/PTC rearrangements, with aberrant RAF-MEK-ERK and/or PI3K pathway activation.
|
26265449 |
2015 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analysis by a reverse transcriptase-polymerase chain reaction method showed that the ret rearrangement-positive tumor contained the PTC/retTPC chimeric transcript, which was reported to be found specifically in thyroid tumors and adenomatous goiter.
|
1381340 |
1992 |
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer.
|
11344225 |
2001 |
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF(V600E) mutation analysis is superior to RAS point mutations and evaluation of RET/PTC rearrangements in the diagnosis of thyroid cancer, even in indeterminate lesions.
|
25333496 |
2015 |
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Common mutations found in thyroid cancer are point mutation of the BRAF and RAS genes as well as RET/PTC and PAX8/PPARγ chromosomal rearrangements.
|
21878896 |
2011 |
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia.
|
9814501 |
1998 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Even though RET/PTC is a specific genetic event in the carcinomas, our results suggested the possibility of RET/PTC as "passenger" abnormalities rather than "driver" oncogenic mutation during thyroid cancer progression, warranting further studies on mechanisms and implication of RET gene instability.
|
19495791 |
2009 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical technique is proved to be a useful tool to detect RFT/PTC activation in thyroid tumors.
|
15368067 |
2005 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, expression of Sin1 and activation of AKT kinase were analyzed in fresh-frozen tissue samples (normal/tumor), primary cell cultures (papillary thyroid carcinoma [PTC]), and an established thyroid cancer cell line (medullary thyroid carcinoma) by Western blotting.
|
25456951 |
2014 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
In fact, it has been demonstrated that: a) RET/PTC is an early event in the process of thyroid carcinogenesis and has a critical role in the generation of the papillary carcinoma; b) RET/PTC activation is essentially restricted to the papillary histotype and to the Hürthle thyroid tumors; c) its incidence increases after exposure to radiations.
|
17891236 |
2007 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the current study, the frequency of PTC/retTPC oncogene in thyroid tumors from Saudi Arabia was investigated.
|
8275421 |
1994 |
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we use an 18 Mb region on 10q11.2-21 containing the RET gene and its recombination partners, the H4 and NCOA4 (ELE1) genes, as a model chromosomal region frequently involved in RET/PTC rearrangements in thyroid cancer.
|
16331264 |
2006 |
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of 265 TC, 34 (12.8%) harbored TERT promoter mutations, including 10/153 (6.5%) conventional papillary TC (CPTC), 8/57 (14.0%) follicular variant PTC, 9/30 (30%) tall cell variant PTC, 1/3 (30%) Hurthle cell thyroid cancer (HTC), 1/5 (20%) follicular TC, and 5/13 (38.5%) poorly differentiated TC.
|
26354077 |
2015 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oncogenic proteins such as Ret/PTC, Ras and BRAF can induce NF-kappaB activation making it an important change in thyroid cancer.
|
17891249 |
2007 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Present data suggest that: (1) the incidence of FAP-associated thyroid cancer probably has been underestimated in the past; (2) intensive screening could detect a larger than expected number of thyroid carcinomas; (3) systematic screening is recommended in patients with ocular patches and genetic mutation in exon 15; (4) Hashimoto-like findings do not exclude carcinoma but are a frequent accompanying finding; (5) despite frequent multicentricity and early lymph node involvement, FAP-associated thyroid tumors seem to have an excellent prognosis, in particular those showing ret-PTC activation.
|
9841749 |
1998 |
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
|
9861322 |
1998 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
RET/PTC rearrangement in thyroid tumors.
|
12114746 |
2002 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ret/PTC activation in benign and malignant thyroid tumors arising in a population exposed to low-dose external-beam irradiation in childhood.
|
15126554 |
2004 |
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
RET/PTC is a characteristic genetic alteration frequently found in radiation-induced thyroid cancer in human populations.
|
22136268 |
2011 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several types of rearrangement known to occur in thyroid cancer, including RET/PTC, NTRK1 and BRAF/AKAP9, are more common in radiation-associated thyroid tumors and RET/PTC can be induced experimentally by exposing human thyroid cells to ionizing radiation.
|
19766698 |
2010 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
The authors investigated the prevalence of RET/PTC in a large number of thyroid tumors from Japanese patients.
|
16015630 |
2005 |
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The molecular pathology of thyroid cancer is now better understood because of our ability to identify RET/PTC rearrangements and BRAF mutations in the aetiopathogenesis of the large majority of PTCs and the high prevalence of RAS mutations and PAX8/PPARgamma rearrangements in follicular patterned carcinomas (FTCs and follicular variant of PTCs).
|
19147628 |
2009 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
The posttest probability of thyroid cancer was 100% for nodules positive for BRAF or RET-PTC, 70% for RAS or PAX8-PPARG, and 88% for molecular cytology overall.
|
24811481 |
2014 |
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
The relatively low prevalence of RET activation in PDCs argues against a major role for RET/PTC in the progression from well to poorly differentiated thyroid tumor phenotypes.
|
11788678 |
2002 |
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Twenty-four (27%) of 89 patients were diagnosed with thyroid cancer (50% papillary thyroid carcinoma [PTC], 50% follicular variant of papillary thyroid carcinoma [FVPTC]).
|
25627462 |
2015 |